For instance, it has been reported that inhibiting miR-363-3p or overexpressing EZH2 could partially reverse the anti-tumor effects of MALAT1 depletion, underscoring the functional axis of MALAT1/miR-363-3p/EZH2 in CRC progression [71]. This evidence concerns the gene EZH2 and colorectal carcinoma.